Search

Your search keyword '"Hervig, T"' showing total 217 results
Start Over Author "Hervig, T" Language english
217 results on '"Hervig, T"'

4. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment

Author

Knutson, F., Osselaer, J., Pierelli, L., Lozano, M., Cid, J., Tardivel, R., Garraud, O., Hervig, T., Domanovic, D., Cukjati, M., Gudmundson, S., Hjalmarsdottir, I. B., Castrillo, A., Gonzalez, R., Brihante, D., Santos, M., Schlenke, P., Elliott, A., Lin, J.-S., Tappe, D., Stassinopoulos, A., Green, J., and Corash, L.

Published
2015
Full Text
View/download PDF

11. Pathogen inactivation of platelet concentrates

Author

Reesink, H. W., Panzer, S., McQuilten, Z. K., Wood, E. M., Marks, D. C., Wendel, S., Trigo, F., Biagini, S., Olyntho, S., Devine, D. V., Mumford, I., Cazenave, J.-P., Rasonglès, P., Garraud, O., Richard, P., Schooneman, F., Vezon, G., Al Radwan, R., Brand, A., Hervig, T., Castro, E., Lozano, M., Navarro, L., Puig, L., Almazán, C., MacLennan, S., Cardigan, R., Franklin, I. M., and Prowse, C.

Published
2010
Full Text
View/download PDF

12. Inventory Management

Author

Devine, D. V., Sher, G. D., Reesink, H. W., Panzer, S., Hetzel, P. A. S., Wong, J. K., Horvath, M., Leitner, G. C., Schennach, H., Nussbaumer, W., Genoe, K., Cioffi, J. M., Givisiez, F. N., Rogerson, M., Howe, D., Delage, G., Sarappa, C., Charbonneau, Y., Fu, Y., Šarlija, D., Vuk, T., Patko, Strauss M., Balija, M., Jukić, I., Ali, A., Auvinen, M.-K., Jaakonsalo, E., Cazenave, J.-P., Waller, C., Kientz, D., David, B., Walther-Wenke, G., Heiden, M., Lin, C. K., Tsoi, W. C., Lee, C. K., Barotine-Toth, K., Sawant, R. B., Murphy, W., Quirke, B., Bowler, P., Shinar, E., Yahalom, V., Aprili, G., Piccoli, P., Gandini, G., Tadokoro, K., Nadarajan, V. S., Kort, W. de, Jansen, N., Flanagan, P., Forsberg, P.-O., Hervig, T., Letowska, M., Lachert, E., Dudziak, K., Antoniewicz-Papis, J., Olim, G. de, Nascimento, F., Hindawi, S., Teo, D., Reddy, R., Scholtz, J., Swanevelder, R., Rovira, L. P., Sauleda, S., Carasa, M. A. V., Vaquero, M. P., Ania, M. A., Gulliksson, H., Holdsworth, S., Cotton, S., Howell, C., Baldwin, C., Cusick, R. M., Geele, G. A., Paden, C., McEvoy, P., Gottschall, J. L., McLaughlin, L. S., Benjamin, R. J., Eder, A., Draper, N. L., AuBuchon, J. P., and de González, León G.

Published
2010
Full Text
View/download PDF

22. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial

Author

Ypma, P.F., Meer, P.F. van der, Heddle, N.M., Hilten, J.A. van, Stijnen, T., Middelburg, R.A., Hervig, T., Bom, J.G. van der, Brand, A., Kerkhoffs, J.L.H., and PREPAReS Study Grp

Subjects
Adult, medicine.medical_specialty, Evidence-based practice, Adolescent, bleeding assessment, Ultraviolet Rays, Riboflavin, Hemorrhage, thrombocytopenia, Platelet Transfusion, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Randomized controlled trial, Clinical Protocols, law, Interim, Clinical endpoint, medicine, Blood-Borne Pathogens, Protocol, Humans, Single-Blind Method, Young adult, Adverse effect, Aged, Protocol (science), pathogen reduction, business.industry, General Medicine, Bacterial Infections, Middle Aged, bleeding, Surgery, Platelet transfusion, Treatment Outcome, Virus Diseases, Emergency medicine, business, 030215 immunology, Haematology (Incl Blood Transfusion)
Abstract

Introduction Patients with chemotherapy-induced thrombocytopaenia frequently experience minor and sometimes severe bleeding complications. Unrestrictive availability of safe and effective blood products is presumed by treating physicians as well as patients. Pathogen reduction technology potentially offers the opportunity to enhance safety by reducing bacterial and viral contamination of platelet products along with a potential reduction of alloimmunisation in patients receiving multiple platelet transfusions. Methods and analysis To test efficacy, a randomised, single-blinded, multicentre controlled trial was designed to evaluate clinical non-inferiority of pathogen-reduced platelet concentrates treated by the Mirasol system, compared with standard plasma-stored platelet concentrates using the percentage of patients with WHO grade ≥2 bleeding complications as the primary endpoint. The upper limit of the 95% CI of the non-inferiority margin was chosen to be a ≤12.5% increase in this percentage. Bleeding symptoms are actively monitored on a daily basis. The adjudication of the bleeding grade is performed by 3 adjudicators, blinded to the platelet product randomisation as well as by an automated computer algorithm. Interim analyses evaluating bleeding complications as well as serious adverse events are performed after each batch of 60 patients. The study started in 2010 and patients will be enrolled up to a maximum of 618 patients, depending on the results of consecutive interim analyses. A flexible stopping rule was designed allowing stopping for non-inferiority or futility. Besides analysing effects of pathogen reduction on clinical efficacy, the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) is designed to answer several other pending questions and translational issues related to bleeding and alloimmunisation, formulated as secondary and tertiary endpoints. Ethics and dissemination Ethics approval was obtained in all 3 participating countries. Results of the main trial and each of the secondary endpoints will be submitted for publication in a peer-reviewed journal. Trial registration number NTR2106; Pre-results.

Published
2016

23. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST)

Author

Heddle, NM, Fung, M, Hervig, T, Szczepiorkowski, ZM, Torretta, L, Arnold, E, Lane, S, and Murphy, MF

Abstract

BACKGROUND: One of the most frequent causes of transfusion-associated morbidity or mortality is the transfusion of the wrong blood to the wrong patient. This problem persists in spite of the incorporation of numerous procedures into the pretransfusion checking process in an effort to improve patient safety. A qualitative study was undertaken to understand this process from the perspective of those who administer blood products and to identify concerns and suggestions to improve safety. STUDY DESIGN AND METHODS: Twelve focus group discussions and seven individual interviews were conducted at six hospitals in five countries (n = 72 individuals). Health care professionals from a variety of clinical areas participated. Data analysis identified common themes using the constant comparison method. RESULTS: Five major themes emerged from the analysis: the pretransfusion checking process, training, policy, error, and monitoring. Findings include the following: staff were aware and appreciative of the seriousness of errors and were receptive to continuous monitoring, the focus was on checking the bag label with the paperwork rather than the bag label with the patient at the bedside, training methods varied with most perceived to have minimal effectiveness, and access to policies was challenging and keeping up to date was difficult. Other factors that could contribute to errors included high volume of workload distractions and interruptions and familiarity or lack of familiarity with patients. CONCLUSIONS: Multiple factors can contribute to errors during the pretransfusion checking limiting the effectiveness of any individual intervention designed to improve safety. Areas of further research to improve safety of blood administration were identified.

Published
2016

24. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST)

Author

Heddle, N, Fung, M, Hervig, T, Szczepiorkowski, Z, Torretta, L, Arnold, E, Lane, S, Murphy, M, and Collaborative, BEST

Abstract

BACKGROUND: One of the most frequent causes of transfusion-associated morbidity or mortality is the transfusion of the wrong blood to the wrong patient. This problem persists in spite of the incorporation of numerous procedures into the pretransfusion checking process in an effort to improve patient safety. A qualitative study was undertaken to understand this process from the perspective of those who administer blood products and to identify concerns and suggestions to improve safety. STUDY DESIGN AND METHODS: Twelve focus group discussions and seven individual interviews were conducted at six hospitals in five countries (n = 72 individuals). Health care professionals from a variety of clinical areas participated. Data analysis identified common themes using the constant comparison method. RESULTS: Five major themes emerged from the analysis: the pretransfusion checking process, training, policy, error, and monitoring. Findings include the following: staff were aware and appreciative of the seriousness of errors and were receptive to continuous monitoring, the focus was on checking the bag label with the paperwork rather than the bag label with the patient at the bedside, training methods varied with most perceived to have minimal effectiveness, and access to policies was challenging and keeping up to date was difficult. Other factors that could contribute to errors included high volume of workload distractions and interruptions and familiarity or lack of familiarity with patients. CONCLUSIONS: Multiple factors can contribute to errors during the pretransfusion checking limiting the effectiveness of any individual intervention designed to improve safety. Areas of further research to improve safety of blood administration were identified.

Published
2016

25. RBC alloantibody prevalence and specificity in a Western Norwegian tertiary hospital.

Author

Erikstein, B. S., Hagen, K. G., and Hervig, T.

Subjects
ERYTHROCYTES, PREGNANT women, BLOOD donors, BLOOD products, BLOOD transfusion
Abstract

SUMMARY Background and Objective: Although several studies focus on red blood cell (RBC) alloantibody distribution in selected patient populations, few address the specificity and frequency in all relevant groups. This study reports alloantibody frequency, distribution and the relationship to age and gender in blood donors, pregnant women and potential recipients of blood products. Methods: This historical cohort study included 55 462 consecutive antibody screening tests from a tertiary Western Norwegian Hospital. Descriptive statistics were performed, and the results were compared with the literature. Results: The detection and immunisation frequency for the whole cohort were 0·39 and 0·51%, respectively, whereas the RBC alloantibody prevalence was 0·73%. The most frequent RBC alloantibodies were anti‐E (20·1%), anti‐M (18·7%), anti‐K (9·8%), anti‐D (8·9%) and anti‐Fy(a) (7·0%). In pregnant women, the most frequent RBC alloantibodies were anti‐M, anti‐D and anti‐Le(a) (20·8, 18·9 and 18·9%, respectively), whereas there was no anti‐K detected. Anti‐E and anti‐M were the dominating RBC alloantibodies in the pre‐transfusion testing of in‐hospital patients (24·1 and 17·1%, respectively). Eighteen (9·2%) persons in the total cohort had two RBC alloantibodies, six persons had three alloantibodies, and two persons had four alloantibodies. Rh and K typing to prevent future immunisations was only performed in 21·0% of the individuals who presented with a new alloantibody; despite that, 50·5% of the detected alloantibodies had such specificities. Conclusions: The immunisation frequency and the level of anti‐K are low compared to national and international studies. Rh and K phenotype‐matched blood transfusions might be a feasible future strategy to further decrease RBC alloantibodies. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

26. Intraoperative transfusion practices in Europe

Author

Meier, J., Filipescu, D., Kozek Langenecker, S., Llau Pitarch, J., Mallett, S., Martus, P., Matot, I., ETPOS collaborators: Accurso, G., Ahrens, N., Akan, M., Åkeröy, K., Aksoy, O., Alanoğlu, Z., Alfredo, M., Alkis, N., Almeida, V., Alousi, M., Alves, C., Amaral, J., Ambrosi, X., Ana, I., Anastase, D., Andersson, M., Andreou, A., Anthopoulos, G., Apanaviciute, D., Arbelaez, A., Arcade, A., Arion Balescu, C., Arun, O., Azenha, M., Bacalbasa, N., Baeten, W., Balandin, A., Barquero López, M., Barsan, V., Bascuas, B., Basora, M., Baumann, H., Bayer, A., Bell, A., Belmonte Cuenca, J., Bengisun, Z., Bento, C., Beran, M., Bermudez Lopez, M., Bernardino, A., Berthelsen, K., Bigat, Z., Bilshiene, D., Bilska, M., Bisbe Vives, E., Biscioni, T., Björn, H., Blom, T., Bogdan Prodan, A., Bogdanovic Dvorscak, M., Boisson, M., Bolten, J., Bona, F., Borg, F., Boros, C., Borys, M., Boveroux, P., Boztug Uz, N., Brettner, F., Brisard, L., Britta de, W., Browne, G., Budow, K., Buerkle, H., Buggy, D., Cain, A., Calancea, E., Calarasu, F., Calder, V., Camci, A., Campiglia, L., Campos, B., Camps, A., Carlos, D., Carreira, C., Carrilho, A., Carvalho, P., Cassinello, C., Cattan, A., Cenni, L., Cerny, V., Ceyda Meço, B., Chesov, I., Chishti, A., Chupin, A., Cikova, A., Cindea, I., Cintula, D., Ciobanasu, R., Clements, D., Cobiletchi, S., Coburn, M., Coghlan, L., Collyer, T., Copotoiu, S., Copotoiu, R., Corneci, D., CORTEGIANI, Andrea, Coskunfirat, O., Costea, D., Czuczwar, M., Davies, K., De Baerdemaeker, L., De Hert, S., Debernardi, F., Decagny, S., Deger Coskunfirat, N., Diana, T., Diana, G., Dias, S., Dickinson, M., Dobisova, A., Dragan, A., Droc, G., Duarte, S., Dunk, N., Ekelund, K., Ekmekçi, P., Elena, C., Ellimah, T., Espie, L., Everett, L., Ferguson, A., Fernandes, M., Fernández, J., Ferner, M., Ferreira, D., Ferrie, R., Flassikova, Z., Fleischer, A., Font, A., Galkova, K., Garcia, I., Garner, M., Gasenkampf, A., Gelmanas, A., Gherghina, V., Gilsanz, F., Giokas, G., Goebel, U., Gomes, P., Gonçalves Aguiar, J., Gonzalez Monzon, V., Gottschalk, A., Gouraud, J., Gramigni, E., Grintescu, I., Grynyuk, A., Grytsan, A., Guasch, E., Gustin, D., Hans, G., Harazim, H., Hervig, T., Hidalgo, F., Higham, C., Hirschauer, N., Hoeft, A., Innerhofer, P., Innerhofer Pompernigg, N., Jacobs, S., Jakobs, N., Jamaer, L., James, S., Jawad, M., Jesus, J., Jhanji, S., Jipa Lavina, N., Jokinen, J., Jovanovic, G., Jubera, M., Kahn, D., Karjagin, J., Kasnik, D., Katsanoulas, K., Kelle, H., Kelleher, M., Kessler, F., Kirigin, B., Kiskira, O., Kivik, P., Klimi, P., Klučka, J., Koers, L., Kontrimaviciut, E., Koopman van Gemert, A., Korfiotis, D., Kosinová, M., Koursoumi, E., Kranke, P., Kresic, M., Krobot, R., Kropman, L., Kulikov, A., Kvolik, S., Kvrgic, I., Kyttari, A., Lagarto, F., Lance, M., Laufenberg, R., Lauwick, S., Lecoq, J., Leech, L., Lidzborski, L., Liliana, H., Linda, F., Lopes, A., Lopez, L., Lopez Alvarez, A., Lorenzi, I., Lorre, G., Lucian, H., Lupis, T., Lupu, M., Macas, A., Macedo, A., Maggi, G., Mallor, T., Manoleli, A., Manolescu, R., Manrique, S., Maquoi, I., Marios Konstantinos, T., Markovic Bozic, J., Markus, W., Marques, M., Martinez, R., Martinez, E., Martínez, E., Martinho, H., Martins, D., Martires, E., Matias, F., Mauff, S., Meale, P., Merz, H., Meybohm, P., Militello, M., Mincu, N., Miranda, M., Mirea, L., Moghildea, V., Moise, A., Molano Diaz, P., Moltó, L., Monedero, P., Moral, V., Moreira, Z., Moret, E., Mulders, F., Munteanu, A., Nadia Diana, K., Nair, A., Neskovic, V., Ninane, V., Nitu, D., Oberhofer, D., Odeberg Wernerman, S., Oganjan, J., Omur, D., Orallo Moran, M., Ozkardesler, S., Pacasová, R., Paklar, N., Pandazi, A., Papaspyros, F., Paraskeuopoulos, T., Parente, S., Paunescu, M., Pavičić Šarić, J., Pereira, F., Pereira, E., Pereira, L., Perry, C., Petri, A., Petrovic, U., Pica, S., Pinheiro, F., Pinto, J., Pinto, F., Piwowarczyk, P., Platteau, S., Poeira, R., Popescu, R., Popica, G., Poredos, P., Prasser, C., Preckel, B., Prospiech, A., Pujol, R., Raimundo, A., RAINERI, Santi Maurizio, Rakic, D., Ramadan, M., Ramazanoğlu, A., Rantis, A., Raquel, F., Rätsep, I., Real, C., Reikvam, T., Reis, L., Rigal, J., Rohner, A., Rokk, A., Roman Fernandez, A., Rosenberger, P., Rossaint, R., Rozec, B., Rudolph, T., Saeed, Y., Safonov, S., Saka, E., Samama, C., Sánchez López, Ó., Sanchez Perez, D., Sanchez Sanchez, Y., Sandeep, V., Sandu, M., Sanlı, S., Saraiva, A., Scarlatescu, E., Schiraldi, R., Schittek, G., Schnitter, B., Schuster, M., Seco, C., Selvi, O., Senard, M., Serra, S., Serrano, H., Shmigelsky, A., Silva, L., Simeson, K., Singh, R., Sipylaite, J., Skitek, K., Skok, I., Smékalová, O., Smirnova, N., Sofia, M., Soler Pedrola, M., Söndergaard, S., Sõrmus, A., Sørvoll, I., Soumelidis, C., Spindler Yesel, A., Stefan, M., Stevanovic, A., Stevikova, J., Stivan, S., Štourač, P., Striteska, J., Strys, L., Suljevic, I., Tania, M., Tareco, G., Tena, B., Theodoraki, K., Tifrea, M., Tikuisis, R., Tolós, R., Tomasi, R., Tomescu, D., Tomkute, G., Tormos, P., Trepenaitis, D., Troyan, G., Unic Stojanovic, D., Unterrainer, A., Uranjek, J., Valsamidis, D., van Dasselaar, N., Van Limmen, J., van Noord, P., van Poorten, J., Vanderlaenen, M., Varela Garcia, O., Velasco, A., Veljovic, M., Vera Bella, J., Vercauteren, M., Verdouw, B., Verenkin, V., Veselovsky, T., Vieira, H., Villar, T., Visnja, I., Voje, M., von Dossow Hanfstingl, V., Von Langen, D., Vorotyntsev, S., Vujanovič, V., Vukovic, R., Watt, P., Werner, E., Wernerman, J., Wittmann, M., Wright, M., Wunder, C., Wyffels, P., Yakymenko, Y., Yıldırım, Ç., Yılmaz, H., Zacharowski, K., Záhorec, R., Zarif, M., Zielinska Skitek, E., Zsisku, L., Selçuk Üniversitesi, Meier, J., Filipescu, D., Kozek-Langenecker, S., Llau Pitarch, J., Mallett, S., Martus, P., Matot, I., ETPOS collaborators: Accurso, G., Ahrens, N., Akan, M., Åkeröy, K., Aksoy, O., Alanoğlu, Z., Alfredo, M., Alkis, N., Almeida, V., Alousi, M., Alves, C., Amaral, J., Ambrosi, X., Ana, I., Anastase, D., Andersson, M., Andreou, A., Anthopoulos, G., Apanaviciute, D., Arbelaez, A., Arcade, A., Arion-Balescu, C., Arun, O., Azenha, M., Bacalbasa, N., Baeten, W., Balandin, A., Barquero López, M., Barsan, V., Bascuas, B., Basora, M., Baumann, H., Bayer, A., Bell, A., Belmonte Cuenca, J., Bengisun, Z., Bento, C., Beran, M., Bermudez Lopez, M., Bernardino, A., Berthelsen, K., Bigat, Z., Bilshiene, D., Bilska, M., Bisbe Vives, E., Biscioni, T., Björn, H., Blom, T., Bogdan Prodan, A., Bogdanovic Dvorscak, M., Boisson, M., Bolten, J., Bona, F., Borg, F., Boros, C., Borys, M., Boveroux, P., Boztug Uz, N., Brettner, F., Brisard, L., Britta de, W., Browne, G., Budow, K., Buerkle, H., Buggy, D., Cain, A., Calancea, E., Calarasu, F., Calder, V., Camci, A., Campiglia, L., Campos, B., Camps, A., Carlos, D., Carreira, C., Carrilho, A., Carvalho, P., Cassinello, C., Cattan, A., Cenni, L., Cerny, V., Ceyda Meço, B., Chesov, I., Chishti, A., Chupin, A., Cikova, A., Cindea, I., Cintula, D., Ciobanasu, R., Clements, D., Cobiletchi, S., Coburn, M., Coghlan, L., Collyer, T., Copotoiu, S., Copotoiu, R., Corneci, D., Cortegiani, A., Coskunfirat, O., Costea, D., Czuczwar, M., Davies, K., De Baerdemaeker, L., De Hert, S., Debernardi, F., Decagny, S., Deger Coskunfirat, N., Diana, T., Diana, G., Dias, S., Dickinson, M., Dobisova, A., Dragan, A., Droc, G., Duarte, S., Dunk, N., Ekelund, K., Ekmekçi, P., Elena, C., Ellimah, T., Espie, L., Everett, L., Ferguson, A., Fernandes, M., Fernández, J., Ferner, M., Ferreira, D., Ferrie, R., Flassikova, Z., Fleischer, A., Font, A., Galkova, K., Garcia, I., Garner, M., Gasenkampf, A., Gelmanas, A., Gherghina, V., Gilsanz, F., Giokas, G., Goebel, U., Gomes, P., Gonçalves Aguiar, J., Gonzalez Monzon, V., Gottschalk, A., Gouraud, J., Gramigni, E., Grintescu, I., Grynyuk, A., Grytsan, A., Guasch, E., Gustin, D., Hans, G., Harazim, H., Hervig, T., Hidalgo, F., Higham, C., Hirschauer, N., Hoeft, A., Innerhofer, P., Innerhofer-Pompernigg, N., Jacobs, S., Jakobs, N., Jamaer, L., James, S., Jawad, M., Jesus, J., Jhanji, S., Jipa Lavina, N., Jokinen, J., Jovanovic, G., Jubera, M., Kahn, D., Karjagin, J., Kasnik, D., Katsanoulas, K., Kelle, H., Kelleher, M., Kessler, F., Kirigin, B., Kiskira, O., Kivik, P., Klimi, P., Klučka, J., Koers, L., Kontrimaviciut, E., Koopman-van Gemert, A., Korfiotis, D., Kosinová, M., Koursoumi, E., Kozek Langenecker, S., Kranke, P., Kresic, M., Krobot, R., Kropman, L., Kulikov, A., Kvolik, S., Kvrgic, I., Kyttari, A., Lagarto, F., Lance, M., Laufenberg, R., Lauwick, S., Lecoq, J., Leech, L., Lidzborski, L., Liliana, H., Linda, F., Lopes, A., Lopez, L., Lopez Alvarez, A., Lorenzi, I., Lorre, G., Lucian, H., Lupis, T., Lupu, M., Macas, A., Macedo, A., Maggi, G., Mallor, T., Manoleli, A., Manolescu, R., Manrique, S., Maquoi, I., Marios-Konstantinos, T., Markovic Bozic, J., Markus, W., Marques, M., Martinez, R., Martinez, E., Martínez, E., Martinho, H., Martins, D., Martires, E., Matias, F., Mauff, S., Meale, P., Merz, H., Meybohm, P., Militello, M., Mincu, N., Miranda, M., Mirea, L., Moghildea, V., Moise, A., Molano Diaz, P., Moltó, L., Monedero, P., Moral, V., Moreira, Z., Moret, E., Mulders, F., Munteanu, A., Nadia Diana, K., Nair, A., Neskovic, V., Ninane, V., Nitu, D., Oberhofer, D., Odeberg-Wernerman, S., Oganjan, J., Omur, D., Orallo Moran, M., Ozkardesler, S., Pacasová, R., Paklar, N., Pandazi, A., Papaspyros, F., Paraskeuopoulos, T., Parente, S., Paunescu, M., Pavičić Šarić, J., Pereira, F., Pereira, E., Pereira, L., Perry, C., Petri, A., Petrovic, U., Pica, S., Pinheiro, F., Pinto, J., Pinto, F., Piwowarczyk, P., Platteau, S., Poeira, R., Popescu, R., Popica, G., Poredos, P., Prasser, C., Preckel, B., Prospiech, A., Pujol, R., Raimundo, A., Raineri, S., Rakic, D., Ramadan, M., Ramazanoğlu, A., Rantis, A., Raquel, F., Rätsep, I., Real, C., Reikvam, T., Reis, L., Rigal, J., Rohner, A., Rokk, A., Roman Fernandez, A., Rosenberger, P., Rossaint, R., Rozec, B., Rudolph, T., Saeed, Y., Safonov, S., Saka, E., Samama, C., Sánchez López, Ó., Sanchez Perez, D., Sanchez Sanchez, Y., Sandeep, V., Sandu, M., Sanlı, S., Saraiva, A., Scarlatescu, E., Schiraldi, R., Schittek, G., Schnitter, B., Schuster, M., Seco, C., Selvi, O., Senard, M., Serra, S., Serrano, H., Shmigelsky, A., Silva, L., Simeson, K., Singh, R., Sipylaite, J., Skitek, K., Skok, I., Smékalová, O., Smirnova, N., Sofia, M., Soler Pedrola, M., Söndergaard, S., Sõrmus, A., Sørvoll, I., Soumelidis, C., Spindler Yesel, A., Stefan, M., Stevanovic, A., Stevikova, J., Stivan, S., Štourač, P., Striteska, J., Strys, L., Suljevic, I., Tania, M., Tareco, G., Tena, B., Theodoraki, K., Tifrea, M., Tikuisis, R., Tolós, R., Tomasi, R., Tomescu, D., Tomkute, G., Tormos, P., Trepenaitis, D., Troyan, G., Unic-Stojanovic, D., Unterrainer, A., Uranjek, J., Valsamidis, D., van Dasselaar, N., Van Limmen, J., van Noord, P., van Poorten, J., Vanderlaenen, M., Varela Garcia, O., Velasco, A., Veljovic, M., Vera Bella, J., Vercauteren, M., Verdouw, B., Verenkin, V., Veselovsky, T., Vieira, H., Villar, T., Visnja, I., Voje, M., von Dossow-Hanfstingl, V., Von Langen, D., Vorotyntsev, S., Vujanovič, V., Vukovic, R., Watt, P., Werner, E., Wernerman, J., Wittmann, M., Wright, M., Wunder, C., Wyffels, P., Yakymenko, Y., Yıldırım, Ç., Yılmaz, H., Zacharowski, K., Záhorec, R., Zarif, M., Zielinska-Skitek, E., Zsisku, L., Anesthesiology, Graduate School, ACS - Amsterdam Cardiovascular Sciences, and AII - Amsterdam institute for Infection and Immunity

Subjects
AUSTRIAN BENCHMARK, Male, Blood transfusion, medicine.medical_treatment, 610 Medizin, anaemia, anesthesia, blood transfusion, surgery, transfusion trigger, 030204 cardiovascular system & hematology, GUIDELINES, surgery, Cohort Studies, 0302 clinical medicine, 030202 anesthesiology, Medicine and Health Sciences, Medicine, Prospective Studies, Prospective cohort study, ddc:610, Research Support, Non-U.S. Gov't, Middle Aged, Hospitals, Europe, Female, Allogeneic transfusion, Cohort study, medicine.medical_specialty, Transfusion rate, Observational Study, anesthesia, blood transfusion, ELECTIVE SURGERY, Clinical Practice, 03 medical and health sciences, Journal Article, anaemia, transfusion trigger, Humans, Blood Transfusion, Elective surgery, CHLC ANS, Intensive care medicine, Intraoperative Care, business.industry, PREOPERATIVE ANEMIA, PATIENT BLOOD MANAGEMENT, Clinical trial, Anesthesiology and Pain Medicine, Emergency medicine, business, Packed red blood cells, REQUIREMENTS
Abstract

PubMed: 26787795, Background: Transfusion of allogeneic blood influences outcome after surgery. Despite widespread availability of transfusion guidelines, transfusion practices might vary among physicians, departments, hospitals and countries. Our aim was to determine the amount of packed red blood cells (pRBC) and blood products transfused intraoperatively, and to describe factors determining transfusion throughout Europe. Methods: We did a prospective observational cohort study enrolling 5803 patients in 126 European centres that received at least one pRBC unit intraoperatively, during a continuous three month period in 2013. Results: The overall intraoperative transfusion rate was 1.8%; 59% of transfusions were at least partially initiated as a result of a physiological transfusion trigger- mostly because of hypotension (55.4%) and/or tachycardia (30.7%). Haemoglobin (Hb)- based transfusion trigger alone initiated only 8.5% of transfusions. The Hb concentration [mean (sd)] just before transfusion was 8.1 (1.7) g dl-1 and increased to 9.8 (1.8) g dl-1 after transfusion. The mean number of intraoperatively transfused pRBC units was 2.5 (2.7) units (median 2). Conclusions: Although European Society of Anaesthesiology transfusion guidelines are moderately implemented in Europe with respect to Hb threshold for transfusion (7-9 g dl-1), there is still an urgent need for further educational efforts that focus on the number of pRBC units to be transfused at this threshold. © 2016 The Author. Published by Oxford University Press on behalf of the British Journal of Anaesthesia.

Published
2016

29. Massive transfusion: changing practice in a single Norwegian centre 2002–2015.

Author

Doughty, H., Apelseth, T. O., Sivertsen, J., Annaniasen, K., and Hervig, T.

Subjects
BLOOD transfusion, HEMORRHAGE, BLOOD platelet transfusion, BLOOD platelets, BLOOD transfusion reaction, HEMAPHERESIS, ADENOSINE triphosphate
Abstract

SUMMARY: Objectives: To describe the change in massive transfusion (MT) practice in a single Norwegian centre throughout the period 2002–2015. Background: MT support for traumatic haemorrhage has changed since the mid‐2000s. However, life‐threatening haemorrhage may occur in other clinical specialties. In 2007, Haukeland University Hospital (HUS) introduced a universal MT programme including education, Acute Transfusion Packages (ATPs) and thromboelastography. Methods/Materials: A retrospective review was performed of all MT episodes defined as ≥10 red cell concentrates (RCC) in 24 h. Episodes were identified using the laboratory information system. Patient records were reviewed manually for demographics, transfusion indication, haemostatic drugs and mortality. The ATPs contained six units RCC, six units Octaplas and two platelet concentrates (four buffy coats/apheresis in platelet additive solution (PAS)). Results: A total of 410 episodes were identified in 410 patients. The mean patient age was 60 years (9–94), with a male predominance (64%); 87·1% of MT episodes were in support of surgery (cardiac services 42·7%; trauma 17·6%), and 29·8% of MTs involved platelet inhibitors, with 82·6% of these undergoing cardiac procedures. MT accounted for 2·8% of all RCCs and 3·4% of platelets issued. The mean ratio of blood components RCC: plasma: platelets changed from 1·0 : 0·37 : 0·39 in 2002–2006 (n = 149) to 1·0 : 0·79 : 0·85 in 2008–2015 (n = 241, P < 0·001). A sub‐analysis showed that cardiac specialities used proportionally more plasma and platelets. Conclusion: The MT programme changed transfusion practice, resulting in greater use of plasma and platelets. MT was primarily used in major surgery. The practice in cardiac surgery may reflect changes in antiplatelet medication. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. Thromboelastography may predict risk of grade 2 bleeding in thrombocytopenic patients.

Author

Opheim, E. N., Apelseth, T. O., Stanworth, S. J., Eide, G. E., and Hervig, T.

Subjects
ELASTOGRAPHY, THROMBOSIS, BLOOD platelet transfusion, HEMORRHAGE, C-reactive protein, POINT-of-care testing
Abstract

Background and objectives Platelet count is used as a prophylactic platelet transfusion trigger, although evidence suggests that it is a poor predictor of bleeding. Thus, alternative tests are required. The primary objective of this study was to compare thromboelastography ( TEG) parameters on days with and without bleeding symptoms. The secondary objectives were to investigate the relationship between TEG parameters and haematological variables, fever, C-reactive protein ( CRP) and platelet transfusion. Materials and methods This is a prospective, observational pilot study of 13 thrombocytopenic, haemato-oncologic patients, over 17 cycles of chemotherapy. Bleeding assessment was performed daily together with a total platelet count ( TPC), reticulated platelet per cent ( RPP) and count ( RPC), haemoglobin, mean platelet volume, white blood cell count ( WBC), CRP and temperature. TEG analyses were performed on weekdays. Results TEG alpha angle was significantly lower on days with World Health Organization ( WHO) grade 2 bleeding than on days without bleeding. Haematologic variables, CRP and platelet transfusion the previous day were associated with the outcome of TEG analysis, but fever was not. Conclusion We found a highly significant correlation between the TEG alpha angle and WHO grade 2 bleeding. This finding suggests that fibrinogen-platelet interactions may affect the bleeding risk in thrombocytopenic patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres.

Author

Meer, P. F., Couture, C., Hervig, T., Kruit, G., Devine, D. V., Korte, D., and Kerkhoffs, J.‐L.

Subjects
BLOOD platelets, BLOOD products, BLOOD substitutes, PLASMA products, BLOOD cells
Abstract

Background For a clinical platelet ( PLT) transfusion trial conducted in three countries, the production of PLT concentrates ( PCs) that were pathogen inactivated with the Mirasol technology was set up and validated. While the Mirasol procedure is applied to an established PLT product, the PLT processing procedure still had to be modified to ensure a treated PC was of sufficient quality. Further, the effect of simulated transport conditions and the effect of ambient light on Mirasol-treated PCs was determined. Study Design and Methods Platelet concentrates in plasma were made from pooled buffy coats followed by Mirasol treatment. To mimic transport conditions, units were left unagitated for 6 h at room temperature. To mimic ambient light exposure, units were held unagitated for 4 h in direct fluorescent tube light. Results Measures had to be taken to allow 7-day storage of treated concentrates. In one site, PCs made from five buffy coats with >450 × 109 PLTs were removed from inventory. Another site went from five to four buffy coats per pool. Interruption of agitation for 6 h on day 3 did not induce meaningful changes in in vitro measures, even when stored up to 7 days. Exposure to ambient light for 4 h, either on day 3 or 6, had no effect on in vitro measures. Conclusion The Mirasol pathogen inactivation process can be implemented in routine, but changes to current PLT processing methods might be needed. Transport conditions and 4-h-long ambient light exposure have no negative effect on the in vitro quality of Mirasol-treated PCs. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

33. A prospective observational study on effects of fever on red cell transfusion outcome.

Author

Wendelbo, Ø., Netland Opheim, E., Felli Lunde, T. H., Bruserud, Ø., Hervig, T., and Reikvam, H.

Subjects
FEVER, RED blood cell transfusion, HEMOGLOBINS, DIRECT Coombs' test, SPLENECTOMY
Abstract

The effects of fever on red cell transfusions are not well documented. In this pilot study, we have compared the outcome of red-blood-cell transfusions in haematologic patients with and without fever. The results indicate that haemoglobin increment per unit is significantly lower in febrile patients receiving red cell transfusions than in patients without fever. These findings are in line with earlier findings in preclinical studies. Larger studies are necessary to confirm our results, and laboratory studies should be conducted to investigate the underlying mechanisms. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

36. Plasma total homocysteine response to oral doses of folic acid and pyridoxine hydrochloride (vitamin B[sub 6]) in healthy individuals. Oral doses of vitamin B[sub 6] reduce concentrations of serum folate.

Author

Mansoor, M. A., Kristensen, O., Hervig, T., Bates, C. J., Pentieva, K., Vefring, H., Osland, A., Berge, T., Drabløs, P. A., Hetland, Ø., and Rolfsen, S.

Subjects
HOMOCYSTEINE, BLOOD plasma, FOLIC acid, VITAMIN B6
Abstract

Plasma total homocysteine response was compared in four groups of healthy individuals given orally divided doses of vitamin supplementations for a duration of 5 weeks. The vitamin supplements; A, 0.3 mg folic acid; B, 120 mg vitamin B[sub 6]; C, combination of 0.3 mg folic acid and 120 mg vitamin B[sub 6] or D, 0.6 mg folic acid reduced the concentrations of plasma total homocysteine 20, 17, 32 and 24%, respectively. However, the intergroup comparisons did not show a significant difference in the effects of vitamin supplements. Multivariate analysis with correction for differences in pre-supplement values indicated a significant effect of vitamin B[sub 6] supplementation on plasma total homocysteine and serum folate. Our data show that plasma total homocysteine concentrations are reduced with low to medium divided doses of folic acid alone or in combination with vitamin B[sub 6]. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

45. Implementing a patient blood management program in Norway: Where to start?

Author

Espinosa, A., Arsenovic, M., Hervig, T., Sundic, T., Aandahl, A., Kronborg, J., and Seghatchian, J.

Subjects
*HEMOGLOBINS, *ELECTIVE surgery, *BLOOD products, *RED blood cell transfusion
Abstract

Norway has recently established a working group to implement a national patient blood management (PBM) program. Although benchmarking regarding blood usage is challenging in Norway due to legal barriers, a survey was sent to different hospitals to identify possible areas to be prioritized in the first phase of the PBM program. Among them, optimizing the patient's hemoglobin level before elective surgery and implementing electronic check-lists for the indication of transfusion when ordering blood products are two measures that may have a considerable impact on blood usage. The results of the survey also showed that patients may receive a red blood cell transfusion at hemoglobin levels that are higher than those internationally recommended. Since there are no national guidelines for the use of blood products, agreement regarding hemoglobin thresholds is essential to reduce variation in transfusion practice. To achieve these goals, the transfusion specialist plays a key role in promoting the principles behind the PBM concept at the local hospital. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

46. Ancient human genomes suggest three ancestral populations for present-day Europeans

Author

Joanna L. Mountain, Michael F. Hammer, Ruslan Ruizbakiev, Cesare de Filippo, Kumarasamy Thangaraj, David E. C. Cole, Haim Ben-Ami, Leila Laredj, Mark Lipson, Jüri Parik, Valentino Romano, Andres Ruiz-Linares, Fouad Berrada, Dominique Delsate, Ugur Hodoglugil, Antti Sajantila, Olga Utevska, Shahlo Turdikulova, Tor Hervig, Ludmila P. Osipova, Hovhannes Sahakyan, Robert W. Mahley, Ramiro Barrantes, Kirsten I. Bos, Stanislav Dryomov, Peter H. Sudmant, Nadin Rohland, Heng Li, Gabriel Renaud, Mikhail Voevoda, Claudio M. Bravi, Jean-Michel Guinet, Rem I. Sukernik, Joachim Wahl, Matthias Meyer, Christos Economou, Kay Prüfer, Graciela Bailliet, Mait Metspalu, Mikhail Churnosov, Iosif Lazaridis, Johannes Krause, Bonnie Berger, Levon Yepiskoposyan, Francesca Brisighelli, Francesco Calì, Irene Gallego Romero, Oleg Balanovsky, George Ayodo, Alan Cooper, Alissa Mittnik, Julio Molina, George van Driem, Jean-Michel Dugoujon, Larissa Damba, Fedor Platonov, Nick Patterson, David Reich, Thomas B. Nyambo, David Comas, Olga L. Posukh, Béla Melegh, Draga Toncheva, Alena Kushniarevich, Brenna M. Henn, Montgomery Slatkin, René Vasquez, Elena B. Starikovskaya, Joachim Burger, Ayele Tarekegn, Tatijana Zemunik, Ene Metspalu, Sena Karachanak-Yankova, Lalji Singh, Wolfgang Haak, Susanna Sawyer, Rick A. Kittles, Cheryl A. Winkler, Svante Pääbo, Francisco Rothhammer, Marina Gubina, Pierre Zalloua, Aashish R. Jha, Swapan Mallick, Sergi Castellano, Qiaomei Fu, Desislava Nesheva, Sergey Litvinov, Ingrida Uktveryte, Michael Francken, Cosimo Posth, Theologos Loukidis, Cristian Capelli, Janet Kelso, Sarah A. Tishkoff, Toomas Kivisild, Mark G. Thomas, Elin Fornander, Mercedes Villena, Fredrik Hallgren, Vaidutis Kučinskas, Daniel Corach, George B.J. Busby, Judit Bene, William Klitz, Hamza A. Babiker, Karola Kirsanow, Ruth Bollongino, Rita Khusainova, Evan E. Eichler, Sardana A. Fedorova, Klemetti Näkkäläjärvi, Igor Rudan, Susanne Nordenfelt, Joshua G. Schraiber, Elena Balanovska, Antonio Salas, Richard Villems, Gabriel Bedoya, Elza Khusnutdinova, Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology. Department of Mathematics, Lipson, Mark, Berger Leighton, Bonnie, Lazaridis,I, Patterson,P, Mittnik,A, Renaud,G, Mallick,S, Kirsanow,K, Sudmant,PH, Schraiber,JG, Castellano,S, Lipson,M, Berger,B, Economou,C, Bollongino,R, Fu,Q, Bos,KI, Nordenfelt,S, Li,H, De Filippo,C, Pruefer,K, Sawyer, Posth,C, Haak1,H, Hallgren,F, Fornander,E, Rohland,N, Delsate,D, Francken,M, Guinet,JM, Wah,J, Ayodo,G, Babiker,HA, Bailliet,G, Balanovska,E, Balanovsky,O, Barrantes,R, Bedoya,G, Ben-Ami,H, Bene,J, Berrada,F, Bravi,CM, Brisighelli,F, Busby,GBJ, Cali,F, Churnosov,M, Cole,DEC, Corach,D, Damba,L, van Driem,G, Dryomov,S, Dugoujon,JM, Fedorova,SA, Gallego Romero,I, Gubina,M, Hammer,M, Henn,BM, Hervig,T, Hodoglugi,U, Jha,AR, Karachanak-Yankova,S, Khusainova,R, Khusnutdinova,E, Kittles,R:Kivisild,T, Klitz,W, Kucˇinskas,V, Kushniarevich,A, Laredj,L, Litvinov,S, Loukidis,T, Mahley,RW, Melegh,B, Metspalu,E, Molina,J, Mountain,J, Na¨kka¨la¨ja¨rvi,K, Nesheva,D, Nyambo,T, Osipova,L, Parik,J, Platonov,F, Posukh,O, Romano,V, Rothhammer,F, Rudan,I, Ruizbakiev,R, Sahakyan,H, Sajantila,A, Salas,A, Starikovskaya,EB, Tarekegn,A, Toncheva,D, Turdikulova,S, Uktveryte,I, Utevska,O, Vasquez,R, Villena,M, Voevoda,M, Winkler,CA, Yepiskoposyan,L, Zalloua,P, Zemunik,T, Cooper, Capelli,C, Thomas,MG, Ruiz-inares,A, Tishkoff,SA, Singh,L, Thangaraj,K, Villems,R, Comas,D, Sukernik,R, Metspalu,M, Meyer,M, Eichler,EE, Burger,J, Slatkin,M, Pa¨a¨bo,S, Kelso,J, Reich,D, and Krause,J

Subjects
History, Neanderthal, Biología, Population Dynamics, Present day, Genoma humà, Genome, purl.org/becyt/ford/1 [https], Basal (phylogenetics), Settore BIO/13 - Biologia Applicata, History, Ancient, Genetics, Principal Component Analysis, education.field_of_study, 0303 health sciences, Multidisciplinary, Ancient DNA, 030305 genetics & heredity, food and beverages, Agriculture, Genomics, 3. Good health, Europe, Workforce, CIENCIAS NATURALES Y EXACTAS, Human, Archaeogenetics, Asia, Lineage (genetic), EUROPE, Otras Ciencias Biológicas, European Continental Ancestry Group, Population, Settore BIO/08 - ANTROPOLOGIA, evolution, Europeans, Biology, Article, White People, Ancient, Genètica de poblacions humanes, Human origins, Ciencias Biológicas, 03 medical and health sciences, HUMAN ORIGINS, biology.animal, Humans, ANCIENT DNA, purl.org/becyt/ford/1.6 [https], education, Quantitative Biology - Populations and Evolution, Denisovan, 030304 developmental biology, Genetic diversity, ancient DNA, modern DNA, Europeans, prehistory, Genome, Human, Populations and Evolution (q-bio.PE), biology.organism_classification, Evolutionary biology, FOS: Biological sciences, Upper Paleolithic, Human genome, GENOMICS
Abstract

We sequenced the genomes of a ∼7,000-year-old farmer from Germany and eight ∼8,000-year-old hunter-gatherers from Luxembourg and Sweden. We analysed these and other ancient genomes1,2,3,4 with 2,345 contemporary humans to show that most present-day Europeans derive from at least three highly differentiated populations: west European hunter-gatherers, who contributed ancestry to all Europeans but not to Near Easterners; ancient north Eurasians related to Upper Palaeolithic Siberians3, who contributed to both Europeans and Near Easterners; and early European farmers, who were mainly of Near Eastern origin but also harboured west European hunter-gatherer related ancestry. We model these populations’ deep relationships and show that early European farmers had ∼44% ancestry from a ‘basal Eurasian’ population that split before the diversification of other non-African lineages., Instituto Multidisciplinario de Biología Celular

Published
2014

47. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products.

Author

Horan A, Warreth S, Hervig T, and Waters A

Subjects
Humans, Ireland, Surveys and Questionnaires, Blood Banks, Blood Transfusion methods, Cell- and Tissue-Based Therapy methods
Abstract

Background Aims: The relationship between blood establishments and advanced cellular therapies is evident in several European countries, with some involved in research and development and/or in manufacturing. The aim of the present study was to understand the advanced therapy medicinal product (ATMP) infrastructural, regulatory and logistic requirements needed for the Irish Blood Transfusion Service to support advanced therapeutics in Ireland., Methods: An online survey consisting of 13 questions was distributed in a targeted manner to the identified ATMP stakeholders in Ireland, namely those working in industry, health care, regulatory agencies or education. Subject matter experts in the field were approached and interviewed to gain further insight into the relationship between blood and tissue establishments (BTEs) and ATMPs, to explore the advantages these institutions have in development and to highlight potential challenges for implementation., Results: In total, 84.9% of survey respondents stated that BTEs have a role in the development of advanced therapeutics. Key BTE services identified as applicable to the ATMP sector from both surveys and interviews include the provision of starting materials for research and manufacturing, donor management, use of existing quality and traceability frameworks, product logistic strategies and Good Manufacturing Practice. Challenges for BTE expansion into the sector currently include high costs associated with ATMPs, lack of expertise in these therapies, limited therapeutic populations and no national ATMP strategic plan for Ireland., Conclusions: Blood establishments have services and expertise that can be extended into the advanced therapy sector. The existing knowledge and skill base of BTEs in Ireland should be leveraged to accelerate the development of ATMP strategies for industry and healthcare., Competing Interests: Declaration of Competing Interest The authors have no commercial, proprietary or financial interest in the products or companies described in this article., (Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

48. End of selection criteria based on sexual orientation: An international symposium on alternatives to donation deferral.

Author

Lewin A, Goldman M, Busch MP, Davison K, van de Laar T, Tiberghien P, Shinar E, O'Brien SF, Lambert G, Field S, Hervig T, Tan DHS, Custer B, Drews SJ, Lanteri MC, Klochkov D, Widmer E, Domingue MP, Renaud C, and Germain M

Subjects
Humans, Male, Female, Homosexuality, Male, Patient Selection, Blood Donors, Sexual Behavior, Donor Selection, Sexual and Gender Minorities, HIV Infections epidemiology
Abstract

Background and Objectives: Until recently, gay, bisexual and other men who have sex with men (MSM) were deferred from donating blood for 3-12 months since the last male-to-male sexual contact. This MSM deferral has been discontinued by several high-income countries (HIC) that now perform gender-neutral donor selection., Materials and Methods: An international symposium (held on 20-04-2023) gathered experts from seven HICs to (1) discuss how this paradigm shift might affect the mitigation strategies for transfusion-transmitted infections and (2) address the challenges related to gender-neutral donor selection., Results: Most countries employed a similar approach for implementing a gender-neutral donor selection policy: key stakeholders were consulted; the transition was bridged by time-limited deferrals; donor compliance was monitored; and questions or remarks on anal sex and the number and/or type of sexual partners were often added. Many countries have now adopted a gender-neutral approach in which questions on pre- and post-exposure prophylaxis for human immunodeficiency virus (HIV) have been added (or retained, when already in place). Other countries used mitigation strategies, such as plasma quarantine or pathogen reduction technologies for plasma and/or platelets., Conclusion: The experience with gender-neutral donor selection has been largely positive among the countries covered herein and seems to be acceptable to stakeholders, donors and staff. The post-implementation surveillance data collected so far appear reassuring with regards to safety, although longer observation periods are necessary. The putative risks associated with HIV antiretrovirals should be further investigated., (© 2024 International Society of Blood Transfusion.)

Published
2024
Full Text
View/download PDF

50. Safety and feasibility of platelet transfusion through long catheters in the neonatal intensive care unit: an in vitro study.

Author

Moore CM, Lorusso A, Morgan L, Brazil S, Croxon H, Waters A, Farrelly A, Hervig T, and Curley A

Subjects
Infant, Newborn, Humans, Prospective Studies, Feasibility Studies, Catheters, Platelet Transfusion adverse effects, Intensive Care Units, Neonatal
Abstract

Objective: To assess the safety and feasibility of platelet transfusion through small-bore long lines used in the neonatal intensive care unit (NICU), including double-lumen umbilical venous catheters (UVCs) and 24 G and 28 G peripherally inserted central catheters (PICCs)., Design: Prospective in vitro controlled study., Setting: Blood transfusion service laboratory., Methods: In vitro platelet transfusions were set up as per NICU practice. Transfusion line pressure was monitored. Post-transfusion swirling, presence of aggregates, pH analysis and automated cell count in vitro activation response by flow cytometry assessing CD62P expression were assessed., Main Outcome Measures: All transfusions completed successfully. The rate of infusion was reduced in 5 of 16 transfusions through 28 G lines due to 'pressure high' alarms. There was no difference in swirling values or transfusion aggregate formation, CD62P expression levels, platelet count, platelet distribution width, mean platelet volume, plateletcrit or platelet to large cell ratio across transfusions post-transfusion., Conclusions: This study showed that in vitro platelet transfusion performed through 24 G and 28 G neonatal PICC lines and double-lumen UVCs is non-inferior to 24 G short cannulas, using outcome measures of platelet clumping, platelet activation and line occlusion. This suggests that where available these lines can be used if necessary for platelet transfusion., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results